Phase III diabetes data give Intarcia (and doctors, patients) options
This article was originally published in Scrip
Executive Summary
Intarcia chairman, president and CEO Kurt Graves has more options than ever for advancing his private company's implantable, once-yearly diabetes therapy ITCA 650 now that he has positive results in hand from the first two of four Phase III clinical trials.